ストックスクリーナーアプリを入手
20.27
0.15%
-0.03
プレマーケット:
19.41
-0.86
-4.24%
前日終値:
$20.30
開ける：
$20.31
24時間の取引高:
452.66K
Relative Volume:
0.86
時価総額：
$1.20B
収益：
-
当期純損益:
$-85.21M
株価収益率:
-10.72
EPS:
-1.89
ネットキャッシュフロー:
$-68.53M
1週間 パフォーマンス:
+10.77%
1か月 パフォーマンス:
-1.98%
6か月 パフォーマンス:
+1.20%
1年 パフォーマンス:
-21.43%
1日の値動き範囲:
$19.93
$21.57
1週間の範囲:
$16.80
$21.57
52週間の値動き範囲:
$13.30
$27.20
Enliven Therapeutics Inc Stock (ELVN) Company Profile
ELVN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
20.27 | 1.20B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.16B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
694.99 | 71.65B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.97 | 59.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.73 | 54.79B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
368.36 | 41.77B | 4.98B | 69.59M | 525.67M | 0.5197 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-16 | 開始されました | Goldman | Buy |
| 2024-12-13 | 開始されました | BTIG Research | Buy |
| 2024-09-09 | 開始されました | H.C. Wainwright | Buy |
| 2024-06-11 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-09 | 開始されました | Mizuho | Buy |
| 2023-03-29 | 開始されました | Jefferies | Buy |
すべてを表示
Enliven Therapeutics Inc (ELVN) 最新ニュース
What analyst consensus says on Enliven Therapeutics Inc. stock2025 Institutional Moves & Growth Focused Investment Plans - newser.com
Is Enliven Therapeutics Inc. stock a contrarian buyJuly 2025 Weekly Recap & Reliable Volume Spike Trade Alerts - newser.com
Enliven Therapeutics Inc. stock daily chart insights2025 Momentum Check & Free Community Supported Trade Ideas - newser.com
Decoding Enliven Therapeutics Inc (ELVN): A Strategic SWOT Insig - GuruFocus
Enliven Therapeutics Reports Q3 2025 Financial Results - TipRanks
Published on: 2025-11-12 22:06:18 - newser.com
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update - PR Newswire
Published on: 2025-11-12 18:07:48 - newser.com
Enliven Therapeutics Keeps Moving Forward As Losses Narrow And Cash Holds Strong - Finimize
Enliven Therapeutics Q3 net loss narrows - MarketScreener
Enliven Therapeutics Inc Stock Analysis and ForecastDay Trading Setups & Budget Friendly Growth - earlytimes.in
Published on: 2025-11-11 21:28:07 - newser.com
Enliven Therapeutics Advances Precision Oncology Research - Kalkine Media
Enliven Therapeutics (ELVN) Projected to Post Earnings on Wednesday - Defense World
Will ELVN-001 Enable Enliven Therapeutics To Capture A Share Of The CML Market? - RTTNews
Published on: 2025-11-10 05:45:09 - newser.com
Real time breakdown of Enliven Therapeutics Inc. stock performanceJuly 2025 Selloffs & Smart Investment Allocation Insights - newser.com
Using data filters to optimize entry into Enliven Therapeutics Inc.Breakout Watch & Daily Stock Trend Watchlist - newser.com
Will Enliven Therapeutics Inc. stock continue dividend increasesJuly 2025 Drop Watch & Weekly Momentum Picks - Fundação Cultural do Pará
Can Enliven Therapeutics Inc. stock deliver strong Q4 earningsJobs Report & Free AI Powered Buy and Sell Recommendations - newser.com
Is Enliven Therapeutics Inc. stock attractive for retirement portfoliosMarket Performance Summary & Real-Time Chart Pattern Alerts - fcp.pa.gov.br
Head-To-Head Comparison: Enliven Therapeutics (NASDAQ:ELVN) vs. NLS Pharmaceutics (NASDAQ:NCEL) - Defense World
Is Enliven Therapeutics Inc. stock positioned well for digital economyQuarterly Profit Review & Technical Pattern Recognition Alerts - newser.com
Enliven Therapeutics, Inc. (ELVN) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Published on: 2025-11-05 22:17:31 - newser.com
Is Enliven Therapeutics Inc. stock cheap compared to fundamentalsDollar Strength & Consistent Growth Equity Picks - newser.com
Published on: 2025-11-05 21:38:45 - newser.com
Enliven Therapeutics Inc. recovery potential after sell offJuly 2025 Big Picture & AI Optimized Trade Strategies - newser.com
(ELVN) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Stocks of Enliven Therapeutics Inc (ELVN) are poised to climb above their peers - setenews.com
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 12.3%Here's What Happened - MarketBeat
Is Enliven Therapeutics Inc. stock a buy for dividend growthQuarterly Portfolio Summary & Long-Term Growth Plans - Fundação Cultural do Pará
Fed Watch: Is Enliven Therapeutics Inc. stock positioned well for digital economyQuarterly Portfolio Review & Risk Managed Investment Entry Signals - Fundação Cultural do Pará
Enliven Therapeutics showcases promising results for ELVN-001 in CML trial - Traders Union
Enliven (NASDAQ: ELVN) presents ELVN-001 CML data at ASH 2025 with >1 log transcript declines - Stock Titan
Enliven Therapeutics Inc (ELVN) 財務データ
収益
当期純利益
現金流量
EPS
Enliven Therapeutics Inc (ELVN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER |
Oct 20 '25 |
Sale |
22.08 |
12,500 |
276,025 |
915,188 |
| Kintz Samuel | PRESIDENT AND CEO |
Oct 17 '25 |
Sale |
21.33 |
12,500 |
266,654 |
902,892 |
0.35%
0.75%
大文字化:
|
ボリューム (24 時間):